JUVELOOK Celebrates 1.5 million Vial Milestone

JUVELOOK Celebrates 1.5 million Vial Milestone

VAIM announced that its collagen biostimulator JUVELOOK has exceeded 1.5 million vials in cumulative production as of May 2025.

JUVELOOK is an injectable collagen stimulator that combines PDLLA (Poly D,L-lactide) microparticles with hyaluronic acid (HA). It promotes the natural generation of collagen and elastin, improving skin elasticity and reducing the appearance of wrinkles. As the newly formed collagen gradually breaks down over time, JUVELOOK offers long-lasting results, making it a preferred alternative to traditional HA fillers.

Since its 2019 launch, JUVELOOK has seen rapid global growth. In response to demand, VAIM tripled production by opening a new Daejeon facility in March 2024.

JUVELOOK’s global recognition continues to grow. In March, at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) held in Monaco, JUVELOOK was awarded “Best Injectable for Skin Revitalization,” reinforcing its status as a leading product in the aesthetic industry. The momentum continued in April as JUVELOOK received regulatory approval in Russia and officially launched in the local market with a dedicated event for medical professionals.

A VAIM spokesperson stated, “This milestone reflects JUVELOOK’s growing global presence and our ongoing commitment to innovative, high-quality solutions in medical aesthetics.”

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.